about
Herpes zoster in Germany: quantifying the burden of diseaseHerpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspectiveSimilar herpes zoster incidence across Europe: results from a systematic literature reviewSystematic review of incidence and complications of herpes zoster: towards a global perspective.Prevalence and healthcare utilization of herpes zoster and postherpetic neuralgia in South Korea: disparity among patients with different immune statuses.Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.Herpes zoster surveillance using electronic databases in the Valencian Community (Spain).Disease burden of herpes zoster in Sweden--predominance in the elderly and in women - a register based studyThe humanistic, economic and societal burden of herpes zoster in Europe: a critical reviewA pathway to leadership for adult immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on June 14, 2011Herpes zoster-associated mortality in Europe: a systematic review.Burden of herpes zoster: the direct and comorbidity costs of herpes zoster events in hospitalized patients over 50 years in France.Annual incidence rates of herpes zoster among an immunocompetent population in the United States.Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in GermanyHospital-based herpes zoster diagnoses in Denmark: rate, patient characteristics, and all-cause mortality.Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort studySafety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su): a phase-I, open-label study in Japanese adults.Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly.A systematic review of the cost effectiveness of herpes zoster vaccination.The Epidemiology of Herpes Zoster After Varicella Immunization Under Different Biological Hypotheses: Perspectives From Mathematical Modeling.Cost-effectiveness of a herpes zoster vaccination program among the French elderly peopleIncidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort.Risk factors for herpes zoster in a large cohort of unvaccinated older adults: a prospective cohort study.Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany.Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.Does herpes zoster predispose to giant cell arteritis: a geo-epidemiologic study.Epidemiology and long-term disease burden of herpes zoster and postherpetic neuralgia in Taiwan: a population-based, propensity score-matched cohort study.Herpes Zoster and Diabetes Mellitus: A Review.The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50 Years in Japan: Results of a Markov Model Analysis.Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012.
P2860
Q21261833-449E388B-0B99-497C-9B2A-C0D5D8BCC9B6Q26781940-90CB04FA-54F1-49B7-9B31-CC5F2314F3D0Q26824836-943FC54A-9450-4972-8B0E-BFB6D18322A9Q33795551-98CA61E5-0DD0-4A56-8A50-1516B56799BBQ34125709-204E93D5-03F5-45AC-91BC-7EBED445D079Q35000186-036EC1B5-C36F-4E54-8FCD-13744F2FD9B0Q35008196-4621734F-93FA-4AE7-8702-D2A51587D2ABQ35065255-082DA931-D5BA-412D-AE75-A90ADA64BB53Q35147612-7FCBD98F-ED68-4563-BAF8-C693E9224979Q35606837-E76BC695-AA86-49D9-8F61-F95DC41AE515Q35618741-D236C935-3766-4DFF-9B1B-6BE6C53DE5A5Q35749707-B2698D14-434D-4B2E-A049-B448067F8D3CQ35834938-38B6D463-B887-4AE0-A528-B240069AEAB3Q35887517-26E729FB-42FE-4E82-A228-D286B004FE71Q35942170-72E0FCC6-4683-4CCD-8730-EAEEDB6A263DQ36906351-F02D543A-8CA6-4427-9406-9E51CE2A24D0Q37472498-3E66C6EA-AF34-4EBF-B36B-4C3407D44815Q37713779-36A05FF9-B785-4FDA-B2D4-507759484A5EQ38075493-8A7085EA-B9F4-4D21-9F68-29E1F440A60FQ38781301-CCAF4572-8F3A-49B3-BFD0-CD2BB413CB03Q40591031-CDDDCB7E-8986-47B5-85E2-41C74888719FQ41533836-9DC0AFCC-03D9-420F-89B6-997703AFF98DQ41577013-0BE392A9-1890-4A0A-81EE-38DFA5FBC38BQ42281395-C4E0FB91-83D0-48FC-B67A-4DBC1BBE4C8BQ46941948-D94CE928-C707-4180-9109-8A0CDF612FA3Q47546980-498525AB-B245-4D0A-AE9D-660C478E0D2AQ51761737-A0F998F7-F6A5-4B9C-B6D7-A8F99717C331Q52665372-298153C1-6404-4CE0-B10C-1B581410B560Q54230925-91D30D54-DC8B-411E-91A3-64F103778AE3Q55393981-7A44080B-858F-4C3E-A5A1-B8F4A4A7889A
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Herpes zoster: Burden of disease in France.
@en
Herpes zoster: Burden of disease in France.
@nl
type
label
Herpes zoster: Burden of disease in France.
@en
Herpes zoster: Burden of disease in France.
@nl
prefLabel
Herpes zoster: Burden of disease in France.
@en
Herpes zoster: Burden of disease in France.
@nl
P2093
P1433
P1476
Herpes zoster: Burden of disease in France.
@en
P2093
A Lasserre
C Turbelin
I Bonmarin
O Chosidow
S Gonzalez Chiappe
T Blanchon
P304
P356
10.1016/J.VACCINE.2010.09.074
P407
P577
2010-10-12T00:00:00Z